Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1?. Biziotis OD, Tsakiridis EE, Ali A, Ahmadi E, Wu J, Wang S, Mekhaeil B, Singh K, Menjolian G, Farrell T, Abdulkarim B, Sur RK, Mesci A, Ellis P, Berg T, Bramson JL, Muti P, Steinberg GR, Tsakiridis T. Mol Oncol. 2023 Nov 17;17(11):2235-2256. DOI: 10.1002/1878-0261.13508.

PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia. Alshamleh I, Kurrle N, Makowka P, Bhayadia R, Kumar R, Su?sser S, Seibert M, Ludig D, Wolf S, Koschade SE, Stoschek K, Kreitz J, Fuhrmann DC, Toenges R, Notaro M, Comoglio F, Schuringa JJ, Berg T, Bru?ne B, Krause DS, Klusmann JH, Oellerich T, Schnu?tgen F, Schwalbe H, Serve H. Leukemia. 2023 Dec;37(12):2367-2382. DOI: 10.1038/s41375-023-02041-5. Epub 2023 Nov 7.

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Ali A, Mekhaeil B, Biziotis OD, Tsakiridis EE, Ahmadi E, Wu J, Wang S, Singh K, Menjolian G, Farrell T, Mesci A, Liu S, Berg T, Bramson JL, Steinberg GR, Tsakiridis T. Commun Biol. 2023 Sep 8;6(1):919. DOI: 10.1038/s42003-023-05289-w. Epub 2023 Sep 8.

Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia. Boyd AL, Lu J, Hollands CG, Alsostovar L, Murali S, Reid JC, Ye W, Vandersluis S, Johnson P, ElRafie A, Porras DP, Xenocostas D, Leber A, Leber B, Foley R, Trus M, Berg T, Kawata E, Xenocostas A, Bhatia M.  Cell Rep Med. 2023 Jul 18;4(7):101108. DOI: 10.1016/j.xcrm.2023.101108. Epub 2023 Jul 10.

LSD1 inhibition modulates transcription factor networks in myeloid malignancies. Hartung E, Singh K, Berg T. Frontiers in Oncology-Hematologic Malignancies. 10 Mar 2023; 13;1-13. DOI: 10.3389/fonc.2023.1149754.

Cardiovascular Events among Recipients of Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis. Aghel N, Lui M, Wang V, Khalaf D, Mian H, Hillis C, Walker I, Leber B, Lipton J, Aljama M, Lepic K, Berg T, Garcia-Horton A, Petropoulos JA, Masoom H, and Leong DP. Bone Marrow Transplant. 2023 Feb 27;58:478-490. DOI: 10.1038/s41409-023-01928-2.

A retrospective cohort study of donor cell leukemia. Salter B, Raslan O, Demczuk S, Leber B, Garcia-Horton A, Walker I, Berg T, Butcher D, Lepic KL, McCready E, Wasi P, Khalaf D.  Blood. 15 Nov 2022;140(Suppl.1): 12916-12917. DOI: 10.1182/blood-2022-164643

Review: Epigenetic maintenance strategies after allogeneic stem cell transplantation in acute myeloid leukemia. Yan Y, Upadhyaya R, Zhang VW, Berg T. Exp Hematol. 2022 May 1;109:P1-10.E1. Epub 2022 Mar 12. DOI: 10.1016/j.exphem.2022.03.003.

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses. Tsakiridis EE, Broadfield L, Marcinko K, Biziotis OD, Ali A, Mekhaeil B, Ahmadi E, Singh K, Mesci A, Zacharidis PG, Anagnostopoulos AE, Berg T, Muti P, Steinberg GR, Tsakiridis T.  Transl Oncol. 2021 Aug 31;14(11):101209. DOI: 10.1016/j.tranon.2021.101209.

Proteomic Analysis Reveals Autism-Associated Gene DIXDC1 Regulates Proteins Associated with Mitochondrial Organization and Function. Kwan V, Rosa E, Xing S, Murtaza N, Singh K, Holzapfel N, Berg T, Lu Y, Singh KK. J Proteome Res. 2021 Jan 1;20(1):1052-1062. DOI: 10.1021/acs.jproteome.0c00896.

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C, Wollmer E, Wasch R, Bornhauser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kroger N, Wolschke C, Schleuning M, Gotze KS, Schmid C, Crysandt M, Ebeling E, Wolf D, Wang Y, Bohm A, Thiede C, Haferlach T, Michel C, Bethge W, Wundisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK.  J Clin Oncol. 2020 Sep 10;38(26):2993-3002.

Editorial: Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplants and Lymphoma. Berg T, Mian HS, Meyer RM. JAMA Oncol. 2020 Jul 1;6(7):989-991.

LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. Barth J, Abou-El-Ardat K, Dalic D, Kurrle N, Maier AM, Mohr S, Schütte J, Vassen L, Greve G, Schulz-Fincke J, Schmitt M, Tosic M, Metzger E, Bug G, Khandanpour C, Wagner SA, Lübbert M, Jung M, Serve H, Schüle R, Berg T.  Leukemia. 2019 Jun 24;33(6):1411-1426.

Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia. Kresinsky A, Bauer R, Schnöder TM, Berg T, Meyer D, Ast V, König R, Serve H, Heidel FH, Böhmer FD, Müller JP. Haematologica. 2018 Nov;103(11):e505-e509.

GFI1 is required for RUNX1/ETO positive acute myeloid leukemia. Marneth AE, Botezatu L, Hönes JM, Israël JCL, Schütte J, Lams RF, Bergevoet SM, Groothuis L, Mandoli A, Lo MC, Martens JH, Huls G, Jansen JH, Dührsen U, Berg T, Möröy T, Wichmann C, Zhang DE, van der Reijden BA, Khandanpour C. Haematologica. 2018 Sep;103(9):e395-e399.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen NS, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari ME, Schaap M, Fox CP, Kröger N, Montoto S, Schetelig J. Bone Marrow Transplant. 2018 May 4;54(1):44-52.

Structure-activity studies on N-substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Schulz-Fincke J, Hau M, Barth J, Robaa D, Willmann D, Kürner A, Haas J, Greve G, Haydn T, Fulda S, Lübbert M, Lüdeke S, Berg T, Sippl W, Schüle R, Jung M.  J. Med. Chem. 2018 Jan 20; 144:52-67.

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Bug G, Burchert A, Wagner EA, Kröger N, Berg T, Güller S, Metzelder SK, Wolf A, Hünecke S, Bader P, Schetelig J, Serve H, Ottmann OG. . Leukemia. 2017 Nov; 31(11):2523-2525.

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. Mohr S*, Doebele C*, Comoglio F*, Berg T*, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T. Cancer Cell. 2017 Apr 10;31(4):549-562.e11. * denotes equal contribution

Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia. Lindner S, Berg T, Riemann J, Ajib S, Jedlickova Z, Gueller S, Lang F, Martin H, Serve H, Bacigalupo A, Bug G. Ann Hematol. 2016 May;95(6):1023-5.

NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD. Leukemia. 2016 Feb;30(2):473-83.